Downstream Bioprocessing Market Reaches $11 Billion: Kalorama Information

ROCKVILLE, Md., Oct. 9, 2018 /PRNewswire/ -- The world downstream bioprocessing market reached $11 billion in 2017, according to Kalorama Information. Downstream bioprocessing involves the recovery and purification of biosynthetic products, often pharmaceuticals, from natural sources. These sources may be animal or plant tissue or fermentation broth. Downstream bioprocessing is an essential step in producing pharmaceuticals such as antibiotics, hormones (insulin and human growth hormone), antibodies, and vaccines. The healthcare market research firm's recent report, Downstream Bioprocessing Markets (Chromatography Columns and Resins, Membrane Adsorbers, Filtration Systems, Sensors), analyzes the current and potential world market for downstream bioprocessing, including global market data for downstream bioprocessing components.

Kalorama Information Logo.

"At the forefront of driving growth in the global bioprocessing market is the greater emphasis on developing drugs targeting smaller, specific populations who have specific diseases," said Bruce Carlson, Publisher of Kalorama Information. "Global demand for biopharmaceuticals such as antibodies and vaccines to treat cancer, arthritis, and diabetes is increasing rapidly."

Advances in technology and bioprocessing equipment are making it possible to develop quality biologic drugs. This is increasing the use of bioprocessing equipment, which drives the biopharmaceutical market. The growing numbers of elderly, notably those suffering from chronic illnesses, will help generate a continuing need for novel biotherapeutic drugs. And as demand increases, bioprocessors will need processing technologies and components that will facilitate the production of high quality products. As a result, the significance of the downstream bioprocessing market will grow.

Essentially, the need for cell therapy research, drug discovery, and antibody production all are presenting bioprocessors with niche market opportunities in personalized medicine. After the shortage of vaccines for the pandemic H1N1 virus in 2009, interest in single use technologies surged as vaccine manufacturers realized that they needed to adopt flexible approaches to avoid future vaccine shortages.

Downstream bioprocessing refers to the separation and refinement of bulk bioproduct into a form suitable for its end use. Typically, this processing includes separation, purification and sterilization. Downstream Bioprocessing Markets provides data on the market in total, as well as by the following market segments: chromatography columns and resins, membrane adsorbers, filtration, and sensors. Data points include:

  • World Downstream Bioprocessing Markets, 2016-2021
  • World Downstream Bioprocessing Chromatography Columns and Resins Markets, 2016-2021
  • World Downstream Bioprocessing Membrane Adsorber Market, 2016-2021
  • World Downstream Bioprocessing Filtration Market, 2016-2021
  • World Downstream Bioprocessing Sensor Market, 2016-2021

The total market and its segments are examined from a geographic perspective as well, including breakouts for United States, Western Europe, Eastern Europe, Asia Pacific (China, Japan, S. Korea, India, Others), Latin America, and rest of world.

Downstream Bioprocessing Markets (Chromatography Columns and Resins, Membrane Adsorbers, Filtration Systems, Sensors) profiles companies such as ESI Ultrapure, GE Healthcare, Millipore, Natrix, Pall, Sartorius, and Thermo Fisher Scientific. Bioprocessors must focus on cost effectiveness, so they will pay great attention to production technologies that generate higher productivity and yields. As many of these advanced processing techniques can find use in the production of mainstream biologic therapeutics, biopharmaceuticals of the future will benefit from any efficiencies. For bioprocessors, speed, process innovation, and operational excellence are must-win battles. The report can be found at:

About Kalorama Information

Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on and

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website:   

Press Contact:                                                         
Bruce Carlson
212 807 2262                                                



Cision View original content to download multimedia:

SOURCE Kalorama Information

Back to news